GLP-1s When You Have a History of Disordered Eating

In most cases yes, but not casually and not without support. There is no blanket contraindication in the prescribing information for semaglutide or tirzepatide, and for some people with a history of binge eating the medication is genuinely therapeutic. What has changed in the last two years is that eating disorder clinicians have started publishing explicit guidance, and the consistent message is that the screening step is being skipped.

A 2026 review in the *International Journal of Eating Disorders* described the situation plainly: current prescribing pathways often lack systematic eating disorder screening, multidisciplinary monitoring, and any guidance on how to distinguish medically appropriate appetite reduction from emerging eating disorder psychopathology. In other words, the tools exist, but nobody is required to use them.

The population data suggests this matters at scale. A nationally representative U.S. household survey published in 2025 found that scoring positive on an eating disorder screen was associated with greater interest in and attempts to access GLP-1s for weight loss — and the association was stronger in women. The people most likely to be harmed are, on average, more likely to be seeking the medication.

None of this means you should not take one. It means the honest version of the conversation is: what is my history, who is monitoring me, and what is my plan if the old patterns come back? If your prescriber has not asked about your history, tell them anyway. It changes what a 'good' response to the drug looks like.

Because the drug does one thing — it reduces the drive to eat — and that single effect lands very differently depending on which direction your disorder pulls.

Where it can help: binge eating and loss-of-control eating. GLP-1 receptors in the hypothalamus and the brain's reward circuitry reduce both physiological hunger and the intrusive, repetitive thoughts about food that people call [food noise](/blog/food-noise-what-it-is-and-why-glp1s-quiet-it). For someone whose disorder is characterized by episodes of eating past the point of comfort and feeling unable to stop, turning that signal down can break the cycle. A 2024 systematic review of GLP-1 agonists in binge eating disorder and bulimia nervosa found reductions in binge frequency across the small studies conducted so far, though the evidence base remains thin and short-term.

Where it can harm: restriction, anorexia nervosa, and ARFID. The same appetite suppression that interrupts a binge also makes it dramatically easier to eat almost nothing and feel fine about it. For someone with a restrictive history, the drug removes the main biological obstacle to restriction — hunger. Clinicians describe patients who use the medication to make restriction sustainable, and who experience the absence of hunger not as relief from a symptom but as an achievement.

The grey zone: orthorexia and compulsive weight control. This is where most people actually live. Not a formal diagnosis, but a relationship with food and body that is rigid, rule-bound, and tied to self-worth. A GLP-1 can hand you exactly the tool that rigidity was looking for.

The mechanism is neutral. What determines the outcome is what your mind does with reduced appetite.

A proper pre-start conversation takes about ten minutes and covers four things. If your prescriber does not raise them, you can.

A disordered eating history. Not just 'have you ever been diagnosed with an eating disorder,' which most people answer no to even when the honest answer is complicated. The useful questions are behavioural: Have you ever gone long stretches eating far less than you needed? Have you ever made yourself sick, used laxatives, or exercised to compensate for eating? Have you had periods where you ate large amounts and felt unable to stop? Has your weight ever been a source of clinical concern in either direction?

A validated screener. Clinicians recommend tools such as the SBIRT-ED (Screening, Brief Intervention and Referral to Treatment for Eating Disorders) for adults. These take two minutes and catch things a general conversation misses.

A monitoring plan. What gets checked, how often, and by whom. At minimum: weight trajectory, whether you are meeting a minimum intake, and a check-in on your relationship with eating — not just a number on a scale.

A mental health contact. Ideally established before you start, not after something goes wrong. If you already have a therapist, tell them you are starting the medication.

The uncomfortable reality is that many telehealth GLP-1 pathways are optimized for speed. A five-question intake form and a prescription in twenty minutes is a feature for most customers and a genuine risk for this group. If speed is what you got, you may need to build the rest of the scaffolding yourself.

The tricky part is that early eating disorder relapse on a GLP-1 looks almost identical to the medication working well. Both involve eating less and losing weight. The difference is not in the behaviour, it is in the *relationship* to the behaviour. Here is what to watch for:

Relief rather than neutrality about not eating. The drug working well feels like 'I forgot to have lunch.' Trouble feels like 'I got through the whole day without eating and I feel accomplished.'

Hiding your intake. Downplaying to your partner or doctor how little you have eaten. Eating in front of people specifically so they stop asking.

Deliberately skipping or delaying doses to prolong appetite suppression — or the reverse, taking the dose early because hunger came back and that felt frightening.

Escalating body checking. More mirror time, more pinching, more weighing, as weight drops rather than less.

Fear of the maintenance conversation. A strong negative reaction to your clinician suggesting your weight loss is enough, or to the idea of a maintenance dose.

Return of compensatory behaviours. Exercising to 'earn' food, purging, laxatives.

The number becoming the point again. If the goal was health and it has quietly become the scale, that shift is worth naming out loud.

A useful self-check: if the medication stopped working tomorrow and your appetite came back fully, would you feel relieved or would you feel panic? Panic is information. Our piece on [the fear of regaining weight](/blog/fear-of-regaining-weight-on-glp1-maintenance-anxiety) explores that reaction in more depth.

The core protective strategy is to replace appetite with structure. When hunger is no longer the thing telling you to eat, something else has to.

Set a floor, not a ceiling. This is the most important single change. Most people on a GLP-1 think in terms of maximums. If you have a restrictive history, you need a defined minimum: a calorie floor and a protein floor that you eat regardless of whether you want to. For most midlife women that means not going below roughly 1,200-1,400 calories and hitting a protein target in the range of 1.0-1.2 g per kg of body weight. Our guide on [eating enough on a GLP-1](/blog/eating-enough-on-glp1-during-menopause-calorie-floor) walks through how to set yours.

Eat on a schedule, not on appetite. Three anchored eating occasions per day at set times. Small is fine. Skipped is not.

Make food easy on low-appetite days. Liquid calories count. A protein smoothie you will actually finish beats a plated meal you will push around.

Limit weighing to once a week, or hand the scale to someone else. Daily weighing feeds the exact loop you are trying to avoid.

Keep one person informed. A partner, a friend, a therapist — someone who knows your history and has permission to say 'you don't seem to be eating.'

Do not chase the fastest possible loss. Slower titration and a lower effective dose are legitimate choices. The goal is the health outcome, not the leaderboard.

Plan the maintenance phase before you need it. Deciding in advance what weight you will stop at, while you are still thinking clearly, is far easier than deciding in the moment.

If you recognise yourself in the warning signs, the most useful thing to know is that this is common, it is treatable, and telling someone early makes it much smaller than telling someone late.

Start with whoever prescribed the medication. They need to know, and it changes the clinical picture. This is not a confession; it is a side effect report. A good prescriber will adjust the plan rather than simply stopping the drug, because abrupt discontinuation has its own risks.

Ask for a referral to an eating disorder specialist. General therapists vary enormously in their comfort with this area. Specialist care — ideally someone who understands both eating disorders and metabolic medicine — is worth the wait.

In the U.S., the National Alliance for Eating Disorders runs a free helpline staffed by licensed clinicians who can help you find treatment near you: 1-866-662-1235, weekdays. (The older NEDA helpline is no longer operating.)

Consider involving a registered dietitian with eating disorder training. They are often the most practical member of the team for someone on a GLP-1, because the work is concrete: what to eat, when, how much, on a day when nothing appeals.

One last thing worth saying. Wanting to lose weight and having a complicated history with food are not contradictory, and neither one disqualifies you from care. Plenty of people with a past eating disorder use a GLP-1 safely and well. What separates them is not willpower — it is that somebody was watching alongside them.